Newsfeeds - Spark Newswire

1 minute read

Cantor Fitzgerald Initiates Coverage On Oncolytics Biotech with Overweight Rating, Announces Price Target of C$9

March 6, 7:21 AM

Cantor Fitzgerald analyst Louise Chen initiates coverage on Oncolytics Biotech (TSX:ONC) with a Overweight rating and announces Price Target of C$9.

TSX:ONC

3 minute read

Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS

By Benzinga Newsdesk

December 8, 9:58 AM

Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics

ONCY

2 minute read

Oncolytics Biotech Receives FDA Fast Track Designation For The Treatment Of Advanced/Metastatic Pancreatic Cancer

By Benzinga Newsdesk

December 1, 8:40 AM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with Roche's anti-PD-L1

ONCY

2 minute read

Oncolytics Biotech Partner Adlai Nortye Advances To The Second Dose Escalation Cohort Of The Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment In Breast Cancer

By Benzinga Newsdesk

January 27, 8:26 AM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety,

ONCY

2 minute read

Oncolytics Biotech Provides Enrollment Update On Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial At The 2022 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

By Benzinga Newsdesk

January 20, 9:22 AM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers

ONCY

2 minute read

News

Oncolytics Biotech Announces Preclinical Data Demonstrating The Synergistic Immunotherapeutic Effects Of Pelareorep Combined With Radiotherapy

By Benzinga Newsdesk

September 20, 8:19 AM

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data

ONCY

1 minute read

Oncolytics Biotech Q2 EPS $(0.13) Up From $(0.17) YoY

By Benzinga Newsdesk

August 6, 7:21 AM

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.13) per share. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.

ONCY